<DOC>
	<DOCNO>NCT00180453</DOCNO>
	<brief_summary>Prospective , randomize , control , single-blinded , parallel two-arm , multicenter trial . Test arm : XIENCE V® Everolimus Eluting Coronary Stent System ( stent length : 18mm , diameter : 3.0mm ) Control arm : Metallic stent ( MULTI-LINK VISION® metallic stent ( stent length : 18mm , diameter : 3.0mm ) Follow-up angiographic image intra vascular ultra sound ( IVUS ) 180 day 1 year</brief_summary>
	<brief_title>SPIRIT FIRST Clinical Trial Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System</brief_title>
	<detailed_description>The SPIRIT FIRST clinical trial enroll approximately 60 patient assess feasibility performance XIENCE V® Everolimus Eluting Coronary Stent System treatment patient de novo native coronary artery lesion . In trial , XIENCE V® Everolimus Eluting Coronary Stent System compare MULTI-LINK VISION® metallic stent CE mark FDA approve available commercial use Europe United States . The SPIRIT FIRST Clinical trial enroll approximately 60 patient ( 30 patient test arm 30 patient control arm ) de novo native coronary artery lesion 4 clinical site The Netherlands Germany</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion Criteria 1 . Patient must least 18 year age . 2 . Patient able verbally acknowledge understand associate risk , benefit treatment alternative receive XIENCE™ V Everolimus Eluting Coronary Stent System legally authorize representative provide write informed consent prior stent procedure , approve appropriate Ethics Committee . 3 . Patient must evidence myocardial ischemia ( e.g. , stable unstable angina , silent ischemia , positive functional study ) . 4 . Patient must acceptable candidate coronary artery bypass graft ( CABG ) surgery . 5 . Patient must agree undergo protocolrequired followup examination include angiographic IVUS followup two time point ( 180 day 1 year ) . 6 . Female patient childbearing potential must negative pregnancy test within 7 day treatment , must nursing time treatment . 7 . Female patient childbearing potential must also agree time consent use birth control include second angiographic followup 1 year . Angiographic 1 . Planned single , de novo , type A B1 , native coronary artery lesion treatment . 2 . Target lesion must locate native vessel diameter 3.0 mm assess QCA online . 3 . Target lesion length ≤ 12 mm , assess QCA online . 4 . The target lesion must major artery branch stenosis ≥ 50 % &lt; 100 % assessed QCA online TIMI flow ≥ 1 . Exclusion Criteria 1 . Patient know acute myocardial infarction ( great two time upper limit normal CK presence CKMB ) within 3 day precede index procedure CK return normal limit time procedure . 2 . Patient current history unstable arrhythmia , regardless whether cardiac rhythm management device use ( e.g. , pacemaker , Automatic Implantable Cardioverter Defibrillator ) . 3 . Patient know leave ventricular ejection fraction ≥ 30 % . 4 . Patient receive heart transplant organ transplant wait list organ transplant . 5 . Patient receive schedule receive chemotherapy radiation therapy within 30 day prior procedure . 6 . Patient receive immunosuppression therapy know immunosuppressive disease . 7 . Patient receive chronic anticoagulation therapy ( e.g. , heparin , coumadin ) . 8 . Patient known hypersensitivity contraindication aspirin , heparin , clopidogrel , cobalt , chromium , nickel , tungsten , everolimus , acrylic fluoro polymer contrast sensitivity adequately premedicated . 9 . Patient platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) . 10 . Patient known renal insufficiency ( e.g. , serum creatinine level 2.5 mg/dL , patient dialysis ) . 11 . Patient history bleed diathesis coagulopathy refuse blood transfusion . 12 . Patient cerebrovascular accident ( CVA ) stroke transient ischemic neurological attack ( TIA ) within past six month . 13 . Patient significant GI urinary bleed within past six month . 14 . Patient extensive peripheral vascular disease precludes safe 6 French sheath insertion extreme anticoagulation . 15 . Patient medical illness ( e.g. , cancer congestive heart failure ) recent history substance abuse may cause noncompliance protocol , confound data interpretation associate limited life expectancy ( i.e. , less one year ) . 16 . Patient already participate another investigational use device drug study complete followup phase another trial within last 30 day . 17 . Patient receive drug elute stent within last 1 year . Angiographic 1 . The target lesion meet follow criterion : 1 . Aortoostial location 2 . Unprotected leave main location 3 . Located within 2 mm origin LAD LCX 4 . Located within distal arterial saphenous vein graft 5 . Located within 2 mm bifurcation 6 . Located distal previously implant stent ( major epicardial vessel ) 7 . Located major epicardial vessel previously treat brachytherapy 8 . Located major epicardial vessel previously treat type PCI ( e.g. , POBA , stent , cut balloon , atherectomy ) , except previous treatment occur side branch distal target lesion least 180 day precede index procedure 9 . Involves jail side branch &gt; 2.0 mm diameter 10 . Total occlusion ( TIMI flow 0 ) 11 . Excessive tortuosity proximal within lesion 12 . Extreme angulation ( ≥ 90 % ) proximal within lesion 13 . Moderate heavy calcification 14 . Restenotic previous intervention 2 . The target vessel contain thrombus . 3 . Another significant lesion ( ≥ 40 % DS ) locate major epicardial vessel target lesion . 4 . Patient high probability procedure predilatation stenting require treatment target vessel ( e.g . atherectomy , cut balloon ) . 5 . Patient additional lesion ( ) intervention within 180 day ( prior ) index procedure would require performed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Ischemia</keyword>
</DOC>